
SentiMag® and Sienna+® for sentinel lymph node localisation in breast cancer

Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S)

Record Status

This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.

Citation

Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S). SentiMag® and Sienna+® for sentinel lymph node localisation in breast cancer . Australia: Australian Safety and Efficacy Register of New Interventional Procedures -Surgical (ASERNIP-S). Technology Brief. 2014

Authors' objectives

The current standard-of-care approach for sentinel lymph node (SLN) localisation and biopsy has significant technical and geographical limitations. It may be possible to overcome these through the use of magnetic technologies such as a hand-held magnetometer and an injectable superparamagnetic iron oxide (SPIO) tracer.

Authors' conclusions

Based on the scant but growing body of evidence for this technology, and its potentially significant potential impact on the investigation of SLN localisation in patients with breast cancer, it is recommended that this technology be monitored for a period of 24 months.

Final publication URL

<https://www.health.qld.gov.au/healthpact/docs/briefs/WP175.pdf>

Indexing Status

Subject indexing assigned by CRD

MeSH

Breast Neoplasms; Sentinel Lymph Node Biopsy; Lymph Nodes; Contrast Media; Dextran; Lymphatic Metastasis; Magnetite Nanoparticles; Technetium Tc 99m Aggregated Albumin; Radiopharmaceuticals

Language Published

English

Country of organisation

Australia

English summary

An English language summary is available.

Address for correspondence

199 Ward Street, North Adelaide SA 5006, Australia. Tel: +61 8 8219 0900, Fax: +61 8 8219 0999 Email: asernips@surgeons.org

AccessionNumber

32015000983

Date abstract record published

08/09/2015